Boehringer cleared to manufacture BeiGene's cancer drug for ...

Boehringer Ingelheim is to manufacture the first biologic drug approved in China using a new regulatory system, designed to strengthen the country’s domestic pharma infrastructure.

BeiGene's Brukinsa fails to beat AbbVie/J&J's Ibrutinib in W...

BeiGene’s Brukinsa (zanubrutinib) has failed to outperform its class rival from Johnson & Johnson/AbbVie in the rare white blood cell cancer Waldenstrom’s macroglublinemia (WM).

FDA nod for AZ’s Calquence sets up new Imbruvica showdown

Amgen pays $2.7bn to harness BeiGene’s China marketing muscl...

China’s BeiGene delays US filing for rival to Imbruvica

BeiGene’s plans for an early approval for BTK inhibitor zanubrutinib in the US and to start challenging Janssen/AbbVie’s blockbuster Imbruvica have suffered a setback.